Alzheimer’s Research Study

Several treatments are available to help ease Alzheimer’s symptoms; however, none of these existing treatments are capable of slowing the progression of the disease and protecting the brain from further damage. Clinical researches are developing new treatments that may slow the progression of Alzheimer’s.

The SUVN-502 Study is to test whether an investigational medication,

Optic neuropathy associated with systemic sarcoidosis

Objective: To identify and follow a series of 52 patients with optic neuropathy related to sarcoidosis.

Demographics.

Fifty-two patients were included in the study. The mean (range) age was 42.5 (20–71) years. Thirty-two (61%) were women. Twenty-four were Caucasian, 24 African or Caribbean, and 4 were from South Asia.

Methods: Prospective observational cohort study.

Clinical manifestations of intermediate allele carriers in Huntington disease

Objective: There is controversy about the clinical consequences of intermediate alleles (IAs) in Huntington disease (HD). The main objective of this study was to establish the clinical manifestations of IA carriers for a prospective, international, European HD registry.

Methods: We assessed a cohort of participants at risk with <36 CAG repeats of the huntingtin (HTT) gene.